Sign In
Buy ATAI
$4.53
-0.280 (-5.82%)
At Close: Jun 03, 2026
Johnson & Johnson’s Spravato sales growth signals upside for psychedelics peers like AtaiBeckley
11:18am, Tuesday, 14'th Apr 2026
Johnson & Johnson (NYSE:JNJ)’s Spravato is reinforcing investor interest in the broader psychedelics sector as it reported another quarter of strong sales...
AtaiBeckley to Participate in Upcoming Needham Healthcare Conferences
06:00am, Tuesday, 14'th Apr 2026
Dr. Srinivas Rao, Co-Founder and Chief Executive Officer of AtaiBeckley, will participate in the 25th Annual Needham Virtual Healthcare Conference (April 13 - 16) and the Needham Virtual Psychedelics
Ceres Power shares fall 8.6% as broker downgrades to 'sell' on valuation concerns
07:10am, Thursday, 09'th Apr 2026
Ceres Power Holdings PLC (LSE:CWR, OTC:CPWHF) fell 7% to 320p on Thursday after Peel Hunt downgraded the fuel cell technology developer to 'sell' from...
AtaiBeckley: 'Buy' On New Key Developments For BPL-003 For TRD
03:54pm, Wednesday, 08'th Apr 2026
AtaiBeckley maintains a "Buy" rating, driven by key pipeline advances in psychedelic-based treatments for treatment-resistant depression. The company's BPL-003 achieved robust, rapid, and statisticall
AtaiBeckley Depression Drug Delivers Rapid Day-2 Antidepressant Response
10:21am, Wednesday, 08'th Apr 2026
The company reported a 66.7% antidepressant response rate at Day 2, which has contributed to the stock's upward momentum as broader markets experienced gains on Tuesday.
AtaiBeckley reports rapid response in Phase 2a trial of depression drug BPL-003
08:43am, Wednesday, 08'th Apr 2026
AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) announced that patients in a mid-stage trial of its experimental depression treatment BPL-003 showed improvement within two days of a single dose, with effect
NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by
AtaiBeckley awarded ‘Buy' rating in initial coverage from Deutsche Bank analysts
11:28am, Friday, 27'th Mar 2026
Deutsche Bank has initiated coverage on AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) assigning a 'Buy' rating and setting a price target of $12, implying potential upside of around 320% from current leve
AtaiBeckley awarded ‘Buy’ rating in initial coverage from Deutsche Bank analysts
07:25am, Friday, 27'th Mar 2026
Deutsche Bank has initiated coverage on AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) assigning a 'Buy' rating and setting a price target of $12, implying...
AtaiBeckley added to major US indices, increasing reach among passive investors
08:38am, Tuesday, 24'th Mar 2026
AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) announced that it has been added to a series of major US equity benchmark indices, a move that is expected to increase its visibility among institutional inve
Inclusion in U.S. CRSP® benchmark indices triggers mandatory position-building by passive index funds tracking more than $3 trillion in AUM, including the world's largest mutual fund Expands market p
AtaiBeckley added to major US indices, increasing reach among passive investors
04:36am, Tuesday, 24'th Mar 2026
AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) announced that it has been added to a series of major US equity benchmark indices, a move that is expected to...
AtaiBeckley: BPL-003 Phase 3 Momentum Keeps Me Bullish
08:03am, Thursday, 19'th Mar 2026
AtaiBeckley is a clinical-stage psychedelic biotech targeting TRD and SAD, with BPL-003 as its lead value driver. BPL-003 posted encouraging depression data and has the FDA's Breakthrough Therapy Desi
AtaiBeckley reports rapid, sustained antidepressant effects in Phase 2a study of BPL-003
09:12am, Tuesday, 17'th Mar 2026
AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) has announced the publication of results from its ongoing Phase 2a clinical study of its investigational treatment for treatment-resistant depression (TRD), B
AtaiBeckley outlines plans for Phase 3 trials of BPL-003 in treatment-resistant depression at Investor Day
09:12am, Tuesday, 10'th Mar 2026
AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) has highlighted progress across its clinical pipeline and reaffirmed its financial outlook during its 2026 Virtual Investor Day, outlining plans to advance it
